(2014) Molecular Medicine , 20(1): 658666 Phase 2 clinical study confirming ARA-290 (4 mg daily 28 days) improved HbA1c, lipid profiles, and neuropathic symptoms in type 2 diabetes patients over 56 days
The containers may be glass vials, plastic vials, or polyampules
This lack of significant improvement may be attributed to the activation of VEGF-independent angiogenic pathways, the recruitment of proangiogenic stromal cells, the induction of vasculogenesis or even the dose of the antiangiogenic agent used, which may reduce the size of blood vessel pores, further obstructing the delivery of this antibody [30, 39, 40]
Delivered via Canada Post Xpresspost
Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RGS, Greig NH, et al